The diabetic population in Japan has been growing. Diabetic patients are prone to cardiovascular disease, and diabetes coexisting with hypertension has a worse outcome than either alone. 1 Numerous studies and guidelines have shown that the control of hypertension targeting blood pressure (BP) below 130/80 mm Hg or home BP below 125/75 mm Hg is essential for the treatment of diabetes. 2, 3 Home (or self-monitored) BP has been shown to be a better marker than conventional clinic BP for predicting cardiovascular events 4,5 and target-organ damage 6-8 in hypertensive populations. Because of its good reproducibility, home BP was suggested for use in clinical practice and clinical trials. 9, 10 This is also true for diabetic subjects. It has been shown that morning hypertension evaluated by home BP monitoring was better correlated with microvascular complications than clinic BP. 11-13 However, few studies have shown the effect of aggressive BP-lowering therapy targeting on morning BP at home. Therefore, the hypotheses tested in this subanalysis of the Japan Morning Surge-1 (JMS-1) study were that home BP is more closely associated with target-organ damage than office BP, and that the impact of home BP measurement is enhanced by the presence of type 2 diabetes (T2DM). As surrogate markers of target organ damage, we selected urinary albumin excretion (UAR), which is recognized in hypertension guidelines as a cardiovascular risk factor.
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The diabetic population in Japan has been growing. Diabetic patients are prone to cardiovascular disease, and diabetes coexisting with hypertension has a worse outcome than either alone. 1 Numerous studies and guidelines have shown that the control of hypertension targeting blood pressure (BP) below 130/80 mm Hg or home BP below 125/75 mm Hg is essential for the treatment of diabetes. 2, 3 Home (or self-monitored) BP has been shown to be a better marker than conventional clinic BP for predicting cardiovascular events 4, 5 and target-organ damage [6] [7] [8] in hypertensive populations. Because of its good reproducibility, home BP was suggested for use in clinical practice and clinical trials. 9, 10 This is also true for diabetic subjects. It has been shown that morning hypertension evaluated by home BP monitoring was better correlated with microvascular complications than clinic BP. [11] [12] [13] However, few studies have shown the effect of aggressive BP-lowering therapy targeting on morning BP at home.
Therefore, the hypotheses tested in this subanalysis of the Japan Morning Surge-1 (JMS-1) study were that home BP is more closely associated with target-organ damage than office BP, and that the impact of home BP measurement is enhanced by the presence of type 2 diabetes (T2DM). As surrogate markers of target organ damage, we selected urinary albumin excretion (UAR), which is recognized in hypertension guidelines as a cardiovascular risk factor.
Methods
Study design. The present work was a substudy of the JMS-1 study, which was originally designed to investigate the effect of doxazosin-a commonly used medication for treating hypertension in Japan that has been shown to selectively lower morning BP 14,15 -on surrogate markers of target on damage, guided
Background
The significance of home blood pressure (BP) measurement in type 2 diabetes (T2DM) has not been well investigated. We aimed to test the hypotheses that home BP is more closely associated with targetorgan damage than clinic BP, and that the presence of prediabetes/ T2DM enhances the impact of home BP measurement.
Methods
We studied 551 hypertensives (99 diabetics and 452 nondiabetics) whose self-measured systolic BP (SBP) was >135 mm Hg while on medication. The subjects were followed for 6 months after allocation to either a control group or an active treatment group. The changes in clinic BP and home BP were analyzed in relation to the changes in the spot urine albumin-creatinine ratio (UaR).
results
The extent of clinic and home BP reduction was similar between the diabetic and nondiabetic groups. The change in UaR in nondiabetics was significantly associated with the extent of SBP reduction in the clinic (r = 0.19), morning (r = 0.33), and evening (r = 0.22, all P < 0.01). In contrast, in the diabetic group, the change in UaR was significantly associated with the changes in morning SBP (r = 0.23, P = 0.02) and evening SBP (r = 0.39, P < 0.001), but not with clinic BP. The correlation with evening SBP in the diabetic group tended to be stronger than the nondiabetic group.
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by self-monitored morning BP at home. The analysis of the JMS-1 data reported in this article was not the primary focus of the study, the results of which were described elsewhere. 16 The detailed protocol was described in our recent publication. 17 Briefly, the JMS-1 study includes hypertensive outpatients with elevated morning systolic BP (SBP) (>135 mm Hg) as assessed by self-measured BP monitoring at home. The study was conducted from 1 August 2003, to August 2005 by 20 doctors at 16 institutions (7 primary practices, 8 hospital-based outpatient clinics, and 1 specialized university hospital) in Japan. The ethics committees of the internal review board at Jichi Medical University School of Medicine (Tochigi, Japan), approved the protocol. Written informed consent was obtained from each subject examined in this study.
Study subjects. We studied 551 hypertensive subjects, whose morning SBP levels measured by home BP monitoring were >135 mm Hg while on stable antihypertensive medication at the time of enrollment. As reported in our recent publication of this study, 16 551 subjects completed the study.
A patient was considered diabetic or prediabetic if he or she had either a history of diabetes or hemoglobin A 1c level >5.8%. We excluded subjects who had arrhythmia, a history or symptoms of heart failure, possible chronic kidney disease (serum creatinine >1.3 mg/dl in women, >1.5 mg/dl in men 3 ), orthostatic hypotension, dementia, malignancy, chronic inflammatory disease, and those subjects who were taking α-or β-blockers.
BP measurements.
Morning BP was measured within 1 h after waking, after urination, and before breakfast and the taking antihypertensive medication. Evening BP was measured before going to bed, and patients were instructed to avoid measuring evening BP just after taking a bath, drinking alcohol, or smoking. Clinic BP was measured at the office using the same automated device that was used for self-measured BP at home. 17 Morning BP and evening BP were measured at home using a validated oscillometric device, the HEM-705IT (Omron Healthcare, Kyoto, Japan) 18 according to the Japanese Society of Hypertension Guidelines for Management of Hypertension. 19 Two BP measurements were made on each occasion in the sitting position, separated by a 30-s interval, and BP analysis was conducted using the BP readings of two measurements for 3 days (12 readings in total: 6 morning and 6 evening) in the sitting position. Clinic BP was measured by the HEM-705IT and calculated as the average of two consecutive measurements. Pulse pressure was defined as SBP minus diastolic BP; mean BP was defined as diastolic BP plus one-third of PP. We set three different targets of morning home BP (morning BP: 135/85 mm Hg, 130/80 mm Hg, and 125/75 mm Hg) to check the percentage of subjects achieving for each target BP level.
Blood and urine assessments. Blood and urine samples were collected at each clinic in the morning and in a fasting state at enrolment and after the sixth month of the study. Spot samples of urine were collected in the morning. 17 Urinary protein was measured qualitatively as a part of clinical practice. The criteria of the measurement was expressed as 0 for urinary protein negative, 1 in cases of urinary protein +, ++, and +++. UAR was measured using the immunoturbidimetric method (Mitsubishi Chemical Iatron, Tokyo, Japan), and expressed as the urine albumin-creatinine ratio (UAR, mg/g). UAR is recognized in hypertension guidelines as a cardiovascular risk factor, and a surrogate of renal target-organ damage. 20, 21 Both serum and urine creatinine were measured by the Jaffe reaction without deproteinization and then quantified by a photometric method. All assays were performed at Mitsubishi Biochemical Laboratory, and the intra/intercoefficients of variation were 1.52/2.48% for urinary albumin and 6.11/7.19% for B-type natriuretic peptide. Estimated glomerular filtration rate (ml/ min) was calculated by the Cockcroft-Gault formula: Ccr = (140 -age × weight)/(Pcr × 72) (× 0.85 for females).
Statistical analyses. Data were expressed as the mean (±s.d.) or percentage. As the UAR distributions were highly positively skewed, these parameters were log-transformed before statistical analyses. The χ 2 -test was used to evaluate differences in prevalence rates. Unpaired t-tests were used to compare mean values for the two groups, and paired t-tests were used to test within-group temporal changes in means. Multiple linear regression analyses were performed to estimate and test the independent effects of changes in BP measures on changes in UAR adjusting for age, sex, BMI, current smoking, hyperlipidemia, and clinic BP at baseline. Differences with a P value < 0.05 (two-tailed) were considered statistically significant. All statistical analyses were performed with SPSS version 13.0 (SPSS, Chicago, IL).
results characteristics of the population
The characteristics of the subjects in the diabetic and nondiabetic groups are presented in Table 1 . The subjects with diabetes were younger, heavier, had a longer duration of hypertension, and had higher clinic and home pulse rates. Otherwise, there were no significant differences in baseline characteristics between the groups. By definition, the diabetic group had a higher hemoglobin A 1c level and a higher proportion of antidiabetic drug use, but the rate of angiotensin-converting enzyme inhibitor angiotensin receptor blocker was not different between the groups. The dose of α-blocker doxazosin (3.4 ± 1.1 vs. 3.4 ± 1.1 mg, P = 0.98) and the use of β-blockers (28.8 vs. 23.2%, P = 0.27) were similar between the nondiabetes mellitus (DM) group and DM groups.
As shown in Table 2 , clinic and home SBP and diastolic BPs were reduced more in the added treatment group than in the control group. This was also the pattern in both the DM and non-DM groups. Table 3 shows the percentages of achieved BP levels in the DM and non-DM groups. Compared to the control group, the rate of subjects achieving each target BP level (morning BP < 135/85 mm Hg, <130/80 mm Hg, and <125/75 mm Hg) was almost doubled in the added treatment group. Figure 1 shows the relationships between the changes in clinic and home BP levels and the change in UAR before and after treatment. In the non-DM group, the changes in all three BP measures (clinic, morning, and evening BP) were significantly associated with the change in UAR; in particular, the change in morning SBP was closely associated with the change in UAR. On the other hand, in the DM group, the change in clinic BP was not associated with the change in UAR. The change in the evening SBP was closely associated with the change in UAR, as well as the change in morning SBP. When the two correlation coefficients between the non-DM and DM groups were compared by z-statistics, the P values of the correlation coefficients were 0.11 for clinic SBP, n.s. for morning SBP, and 0.09 for evening SBP. UAR was reduced significantly by the added treatment in the non-DM group, but the reduction in UAR was not enhanced by added treatment in the DM group (Table 4) . Finally, we performed multiple linear regression analysis to clarify which home BP measure is independently associated with the change in UAR. As shown in Table 5 , morning BP change was correlated with the change in UAR independent of evening BP change in the non-DM group; whereas evening BP change was correlated with the change in UAR independent of the other.
discussion
In this subanalysis of the JMS-1 study, we showed that in addition to morning BP reduction, the lowering of evening home BP was associated with the reduction of UAR in patients with prediabetes/T2DM. On the other hand, clinic BP reduction was not associated with the change in UAR. This is the first study showing the importance of home BP reduction in diabetic patients compared to nondiabetic patients in the same cohort.
home BP in diabetes
In this study, the change in home BP but not clinic BP was associated with the change in UAR. This is in agreement with previous reports showing that home BP is a better marker than clinic BP for predicting renal target organ damage in hypertensives 16 and type 2 diabetics. 11, 12 The international guidelines for hypertension 2 and diabetes 22 briefly describe out-of-office measurement of BP. In the latest statement from the American Diabetes Association, referring to a paper on out-of-office BP 22 Because there is accumulating evidence that out-of-office BP measurement is better than clinic BP even in diabetic populations, these guidelines should incorporate the use of home BP measurement. Unlike the case in the non-DM group, in the DM group, aggressive BP treatment by adrenergic blockers was not significantly associated with UAR reduction. There are two explanations for this: one is that the regression-to-the-mean phenomenon was affected in the control group because the baseline UAR level was significantly higher in the DM group even in the control group; the other explanation is that the morning BP-lowering effect protected the kidneys because the reduction in morning BP was larger in the control group. 16 However, in the present study, the lack of a difference in the change in UAR in the DM group deserves attention; the additional use of adrenergic blockers may not be sufficient for the improvement of UAR in diabetes. This implies greater renal sympathetic nervous system activity in patients with prediabetes or diabetes.
importance of tight BP control in diabetes
In this study, the antihypertensive effect was similar between the DM and non-DM groups. Even when the target BP level was defined by three levels, the achievement rates were similar. There is a consensus that, in patients with T2DM, aggressive BP lowering is important for preventing cardiovascular disease and microvascular complications, but sometimes hypertension in DM is drug-resistant. 23 The lack of a difference between DM and non-DM in this study would be attributable to the definition of diabetes, in which DM is defined by either a history of diabetes or hemoglobin A 1c level of >5.8%. In the present study, patients with possible chronic kidney disease or a history of heart failure were not included, and the DM group consisted mainly of patients with relatively mild diabetes or prediabetes. It is worth noting that the cardiovascular continuum begins before the onset of diabetes. It has been illustrated that atherosclerotic change can be seen in the stage of prediabetes. 24 Therefore, with regard to aggressive BP lowering, no such border divides diabetes and nondiabetes.
importance of night BP control in diabetes
In this study, a BP change just before going to bed was associated with a reduction in UAR as well as a reduction in morning BP. It has been reported that the proportion of nondipping pattern, a lack of nocturnal dip in BP, was 48.2% in patients with diabetes, compared (38.9%) in the nondiabetic population. 25 Although there are no ambulatory blood pressure monitoring data in this study, it could be speculated that many patients in the DM group have such a pattern because resting heart rates, a measure of autonomic neuropathy, were significantly higher in the DM group than in the non-DM group. There have been many observational studies showing that night time BP evaluated by ambulatory blood pressure monitoring is associated with microvascular complications, 12 target-organ damage, 26 and cardiovascular disease in DM. 27 Furthermore, specific diurnal targets such as clinic BP (i.e., white-coat hypertension), 28 morning BP, 29, 30 or nocturnal rise in BP [31] [32] [33] [34] have been reported to help stratify cardiovascular risk in There are some limitations in this study. First, the number of diabetes/prediabetes is not very large and it could have made type 1 errors in this study. Second, the extent of correlation between the changes in the evening BP and UAR in the diabetes group was not statistically stronger than the changes between those in the nondiabetic group (P = 0.09). The differences of the correlation coefficients between the changes in morning BP and UAR, and changes in evening BP and UAR were relatively small. Third, the significance of UAR as a predictor of renal outcome is not yet established in nondiabetic populations. We used morning urine sample for the measurement of UAR, but did not use first morning voiding sample. In hypertensive patients with prediabetes/T2DM, home BP was more useful than clinic BP for the evaluation of targetorgan damage. In particular, if these nonstatistically significant findings are confirmed in larger studies, it would suggest the hypothesis that aggressive control of evening home BP might 
